StockTipsArenaBeta

BUY CORONA Remedies Limited — Kotak Securities

BUYCORONA Remedies Limited
CORONA Remedies share price target & all analyst calls

byKotak SecuritiesHorizon: 1 year3 Nov 2026via CNBC Awaaz.

Entry₹2,171.1Inferred
Target₹2,345
Total upside +8.01% (call closed)
Stop lossNot given
Exit₹2,3454 Nov 2026, 9:49 am
Target hit+8.01%0.00%upside left
Follow Kotak Securities for new calls(92% target hit, 24 closed calls)Get alertsWatch CORONA for new buy/sell callsGet alertsSee 542 active Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 4 Nov 2026
6 supporting0 opposing
Supports the BUY call (6)

1 advisor has an active short-term BUY call on this stock, issued in the last 14 days

Advisor consensus · adjacent horizon·4 Nov · today

Corona Remedies reported Q2 FY27 revenue of 441.2 crore, a 22.2% year-on-year increase, and EBITDA of 96 crore, a 22.3% increase. The company also received ANVISA GMP certification for its Bhayla faci

BSE · Company Update·30 Oct · 4d ago

(opens in new tab)

CORONA Remedies reported a 22.2% year-on-year revenue growth for Q2 FY27, with net profit reaching Rs 60.18 crore, driven by strong performance in its chronic and semi-chronic portfolios.

NSE · Outcome of Board Meeting·30 Oct · 4d ago

(opens in new tab)

Corona Remedies reported Q2 FY27 revenue of Rs 441.2 crore, a 22.2% year-on-year growth, and net profit of Rs 60.3 crore, a 15.3% year-on-year increase.

BSE · Board Meeting·30 Oct · 4d ago

(opens in new tab)

The company received GMP compliance certification from the Brazilian Health Regulatory Agency (ANVISA).

BSE · Company Update·22 Oct · 2w ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on CORONA Remedies

All analyst calls on CORONA Remedies

More from Kotak Securities

Every call and its outcome